A nurse in a neurology outpatient clinic is caring for a 38-…

A nurse in a neurology outpatient clinic is caring for a 38-year-old client recently diagnosed with epilepsy, prescribed carbamazepine, with HLA-B*1502 genetic testing recommended by the neurologist. The client is worried about who will access their genetic information. Which statement by the nurse best addresses the legal protections for pharmacogenetic testing under current U.S. regulations?

A nurse in a post-coronary intervention clinic is reviewing…

A nurse in a post-coronary intervention clinic is reviewing the medication profile of a client recently prescribed clopidogrel after coronary stent placement. The provider orders pharmacogenetic testing based on FDA recommendations. What is the most appropriate interpretation of the FDA’s pharmacogenetic recommendation for this client?

A nurse in an oncology infusion center is caring for a 52-ye…

A nurse in an oncology infusion center is caring for a 52-year-old client with metastatic colorectal cancer, scheduled to start irinotecan-based chemotherapy. The oncology team orders UGT1A1 genetic testing before treatment begins. Which clinical implications should the nurse anticipate when reviewing the client’s pharmacogenomic results? (Select all that apply.)

A nurse in an acute cardiac care unit is preparing to admini…

A nurse in an acute cardiac care unit is preparing to administer nitroglycerin to a client with chest pain. The provider orders sublingual administration rather than oral tablets. Which statement best describes the pharmacokinetic reason for choosing this administration route?

A nurse is giving a presentation on substance use disorder a…

A nurse is giving a presentation on substance use disorder and is asked for examples of medications that are FDA-approved for maintenance treatment in people with alcohol use disorder (AUD). The nurse knows that all of the following are FDA-approved for the management of AUD, EXCEPT: